This article will reflect on the compensation paid to Patrik De Haes who has served as CEO of Oxurion NV (EBR:OXUR) since 2008. This analysis will also evaluate the appropriateness of CEO compensation when taking into account the earnings and shareholder returns of the company.
See our latest analysis for Oxurion
How Does Total Compensation For Patrik De Haes Compare With Other Companies In The Industry?
Our data indicates that Oxurion NV has a market capitalization of €107m, and total annual CEO compensation was reported as €557k for the year to December 2019. That is, the compensation was roughly the same as last year. In particular, the salary of €469.0k, makes up a huge portion of the total compensation being paid to the CEO.
In comparison with other companies in the industry with market capitalizations under €165m, the reported median total CEO compensation was €325k. Hence, we can conclude that Patrik De Haes is remunerated higher than the industry median.
Component | 2019 | 2018 | Proportion (2019) |
Salary | €469k | €459k | 84% |
Other | €88k | €90k | 16% |
Total Compensation | €557k | €549k | 100% |
Talking in terms of the industry, salary represented approximately 63% of total compensation out of all the companies we analyzed, while other remuneration made up 37% of the pie. It's interesting to note that Oxurion pays out a greater portion of remuneration through salary, compared to the industry. If salary is the major component in total compensation, it suggests that the CEO receives a higher fixed proportion of the total compensation, regardless of performance.
A Look at Oxurion NV's Growth Numbers
Oxurion NV has reduced its earnings per share by 39% a year over the last three years. The trailing twelve months of revenue was pretty much the same as the prior period.
The decline in EPS is a bit concerning. And the flat revenue is seriously uninspiring. These factors suggest that the business performance wouldn't really justify a high pay packet for the CEO. Looking ahead, you might want to check this free visual report on analyst forecasts for the company's future earnings..
Has Oxurion NV Been A Good Investment?
Since shareholders would have lost about 19% over three years, some Oxurion NV investors would surely be feeling negative emotions. So shareholders would probably want the company to be lessto generous with CEO compensation.
In Summary...
As we touched on above, Oxurion NV is currently paying its CEO higher than the median pay for CEOs of companies belonging to the same industry and with similar market capitalizations. This doesn't look good against shareholder returns, which have been negative for the past three years. Arguably worse, we've been waiting for positive EPS growth for the last three years. Understandably, the company's shareholders might have some questions about the CEO's remuneration, given the disappointing performance.
We can learn a lot about a company by studying its CEO compensation trends, along with looking at other aspects of the business. In our study, we found 3 warning signs for Oxurion you should be aware of, and 1 of them is a bit unpleasant.
Switching gears from Oxurion, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.
If you’re looking to trade Oxurion, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
About ENXTBR:OXUR
Oxurion
A biopharmaceutical company, develops medicines to prevent blindness.
Medium-low and overvalued.